Maxim Group analyst, Caroline Palomeque, reiterated her Buy rating on shares of VistaGen Therapeutics (NASDAQ: VTGN) after the FDA Psychopharmacologic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE